|
The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data |
Kievit W, Adang E M, Fransen J, Kuper H H, Van De Laar M A, Jansen T L, De Gendt C M, De Rooij D J, Brus H L, Van Oijen P C, Van Riel P C |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Kievit W, Adang E M, Fransen J, Kuper H H, Van De Laar M A, Jansen T L, De Gendt C M, De Rooij D J, Brus H L, Van Oijen P C, Van Riel P C. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Annals of the Rheumatic Diseases 2008; 67(9): 1229-1234 Indexing Status Subject indexing assigned by NLM MeSH Adalimumab; Adult; Aged; Antibodies, Monoclonal /economics /therapeutic use; Antibodies, Monoclonal, Humanized; Antirheumatic Agents /economics /therapeutic use; Arthritis, Rheumatoid /drug therapy /economics; Drug Costs /statistics & Drug Therapy, Combination; Epidemiologic Methods; Etanercept; Female; Glucocorticoids /economics /therapeutic use; Humans; Immunoglobulin G /economics /therapeutic use; Infliximab; Male; Middle Aged; Netherlands; Quality of Life; Receptors, Tumor Necrosis Factor /therapeutic use; Severity of Illness Index; Tumor Necrosis Factor-alpha /antagonists & inhibitors; numerical data AccessionNumber 22008101800 Date bibliographic record published 02/03/2009 |
|
|
|